Targeting T cells is a promising approach in cancer treatment. The two main approaches for T cell redirection involve genetic modification with chimeric antigen receptors (CAR) and use of recombinant proteins designated bispecific T cell engagers (BiTE). While they have demonstrated encouraging results in patients with hematologic cancers, they also come with their bag of side effects – CRS, neurologic adverse effects. They are also yet to prove themselves in solid tumors. Innovators are trying to overcome these issues with new approaches. In this digest, we are focusing on recent clinical, regulatory updates and collaborations of NKT cell therapies and BiTEs